Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Current Reports on Form 8-K, proxy materials, and other documents filed with the Securities and Exchange Commission. As an emerging growth biopharmaceutical company focused on anticoagulant therapies, Cadrenal uses these filings to report material events, governance matters, and financing activities that shape its clinical and corporate trajectory.
Investors researching CVKD can use this page to review Form 8-K filings that describe offerings of common stock and warrants, at-the-market equity programs, and other capital-raising transactions. Additional 8-K reports furnish quarterly financial results, including research and development spending and general and administrative expenses, which help illustrate how resources are being allocated to programs such as tecarfarin, frunexian, and VLX-1005.
The company’s definitive proxy statement on Schedule 14A offers detail on board composition, annual meeting proposals, and governance practices. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide broader context on risk factors, clinical development plans, and the status of regulatory designations for Cadrenal’s anticoagulation pipeline.
Stock Titan enhances this document set with AI-powered summaries that explain the key points of lengthy filings in plain language. Users can quickly understand the implications of a new financing, changes in capital structure, or updates to clinical strategy without reading every page. The platform also surfaces insider and beneficial ownership information when disclosed, helping users see how management and major holders are aligned with the company’s progress. With real-time updates from EDGAR and AI-generated insights, this page is designed to make Cadrenal’s regulatory record more accessible and easier to interpret.
Cadrenal Therapeutics insider Form 4 summary: Quang Pham, CEO, Chairman, director and reported 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on 09/24/2025 and 09/25/2025. On 09/24/2025 he sold 2,581 shares at $13.99 each, leaving 210,723 shares directly owned after that transaction. On 09/25/2025 he sold 6,790 shares in multiple transactions with a weighted average price of $14.09, leaving 203,933 shares directly owned after those sales. Mr. Pham also has indirect ownership of 200,000 shares held by The PVBQ Living Trust; he is Trustee with sole voting and disposition power and the trust’s sole beneficiary is his child. The filing was signed by an attorney-in-fact on 09/26/2025.
Form 144 filed for Cadrenal Therapeutics, Inc. (CVKD) reporting proposed and recent insider sales. The notice shows a proposed sale of 6,790 common shares through Merrill Lynch (Ponte Vedra Beach, FL) with an aggregate market value of $95,661.94 and an approximate sale date of 09/24/2025 on NASDAQ. The shares were acquired as Founders Shares on 01/25/2022 from the issuer. The filing also discloses sales by Quang X. Pham during the past three months: 3,836 shares on 08/27/2025 (gross proceeds $53,455.56), 1,193 shares on 08/28/2025 (gross proceeds $16,540.64), and 2,581 shares on 09/24/2025 (gross proceeds $36,108), totaling $106,104.20 in gross proceeds.
Form 144 notice for Cadrenal Therapeutics, Inc. (CVKD) reports a proposed sale of 10,900 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $150,202 and an approximate sale date of 09/25/2025 on NASDAQ. The shares were acquired as founders' shares on 05/17/2022 from the issuer and the filer indicates payment was made on that date.
The filing also discloses three recent 10b5-1 sales by Matthew Szot totaling 3,500 shares for gross proceeds of $48,984.95, with trades dated 08/27/2025, 08/28/2025 and 09/24/2025. The filer certifies no undisclosed material adverse information and references a trading plan where applicable.
Form 144 notice for proposed sale of securities (Rule 144) filed for common stock to be sold on 09/24/2025 on NASDAQ. The notice lists 2,581 shares to be sold with an aggregate market value of $36,108 against 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 01/25/2022. Recent sales by the same person are disclosed: 3,836 shares sold on 08/27/2025 for $53,455.56 and 1,193 shares sold on 08/28/2025 for $16,540.64. The filing includes a seller representation about absence of undisclosed material adverse information. Several issuer and filer identification fields in the form are blank or not provided in the supplied content.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying the proposed sale of 1,500 common shares through Morgan Stanley Smith Barney on 09/24/2025 with an aggregate market value of $20,520 and 2,046,854 shares outstanding. The shares were acquired as Founders Shares on 05/17/2022. The filing also discloses recent 10b5-1 sales by the same account on 08/27/2025 (1,600 shares, $22,392) and 08/28/2025 (400 shares, $5,600). The filer certifies no undisclosed material adverse information and indicates reliance on established trading procedures where applicable.
Cadrenal Therapeutics, Inc. reported the outcome of its auditor ratification vote on September 24, 2025. The company disclosed vote totals for the Auditor Ratification Proposal showing 1,207,152 votes in favor, 64,913 votes against, 12,681 abstentions and 0 broker non‑votes. The filing lists Steven Zelenkofske and is signed by Quang X. Pham, Chairman and Chief Executive Officer. This item records a routine corporate governance vote approving the company's independent auditor; no financial results, material transactions, or other operational details were included in the provided text.
Cadrenal Therapeutics insider transaction: The company's Chief Financial Officer, Matthew K. Szot, reported two open-market sales of common stock. He sold 1,600 shares on 08/27/2025 at a weighted-average price of $13.995 and sold 400 shares on 08/28/2025 at $14.00. After the first sale he reported beneficial ownership of 31,733 shares and after the second sale 31,333 shares. The Form 4 indicates these were non-derivative dispositions and includes footnotes that the reported prices reflect multiple trades within the stated ranges.
Cadrenal Therapeutics insider sale disclosure: Quang Pham, who serves as CEO and Chairman and is a director and 10% owner, reported open-market sales of the companys common stock on August 27 and August 28, 2025. On August 27 Mr. Pham sold 3,836 shares at a weighted average price of $13.99, reducing his reported direct beneficial ownership to 214,497 shares. On August 28 he sold 1,193 shares at a weighted average price of $13.99, reducing direct beneficial ownership to 213,304 shares. He also reports indirect ownership of 200,000 shares held by The PVBQ Living Trust, for which he is trustee. The filing indicates the transactions were made pursuant to a written plan consistent with Rule 10b5-1 and is signed by an attorney-in-fact on August 29, 2025.
Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 1,193 common shares through Merrill Lynch on 08/28/2025 with an aggregate market value of $16,540.64. The shares were acquired as founders shares on 01/25/2022 from the company. The filing reports 2,046,854 shares outstanding for the class listed. Separately, the document discloses a recent sale by Quang Pham of 3,836 common shares on 08/27/2025 that generated $53,455.56 in gross proceeds. The issuer name and CIK are not provided in the visible content, and the filer contact details are blank.
Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 declaring a proposed sale of 400 founder shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,572.00. The filing lists 2,046,854 shares outstanding and an approximate sale date of 08/28/2025 on NASDAQ. The shares were acquired as founders shares on 05/17/2022 from the issuer and payment was recorded on the same date. The filing also discloses recent 10b5-1 sales by the same person: 1,600 shares sold on 08/27/2025 for gross proceeds of $22,392.00. The filer affirms compliance statements required under Rule 144 and 10b5-1.